Gamma scintigraphy and biodistribution of 99mTc-cefotaxime sodium in preclinical models of bacterial infection and sterile inflammation

dc.contributor.authorIlem-Ozdemir D.
dc.contributor.authorAsikoglu M.
dc.contributor.authorOzkilic H.
dc.contributor.authorYilmaz F.
dc.contributor.authorHosgor-Limoncu M.
dc.contributor.authorAyhan S.
dc.date.accessioned2024-07-22T08:12:07Z
dc.date.available2024-07-22T08:12:07Z
dc.date.issued2016
dc.description.abstract99mTc-cefotaxime sodium (99mTc-CEF) was developed and standardized under varying conditions of reducing and antioxidant agent concentration, pH, radioactivity dose, and reducing agent type. Labeling studies were performed by changing the selected parameters one by one, and optimum labeling conditions were determined. After observing the conditions for maximum labeling efficiency and stability, lyophilized freeze dry kits were prepared accordingly. Simple method for radiolabeling of CEF with 99mTc has been developed and standardized. Labeling efficiency of 99mTc-CEF was assessed by both radio thin-layer chromatography and radio high-performance liquid chromatography and found higher than 90%. The labeled compound was found to be stable in saline and human serum up to 24 h. Two different freeze dry kits were developed and evaluated. Based on the data obtained from this study, both products were stable for 6 months with high labeling efficiency. The prepared cold kit was found sterile and pyrogen free. The bacterial infection and sterile inflammation imaging capacity of 99mTc-CEF was evaluated. Based on the in vivo studies, 99mTc-CEF has higher uptake in infected and inflamed thigh muscle than healthy thigh muscle. Cefotaxime sodium (CEF) was successfully labeled with 99mTc from newly developed instant kit. Radiochemical purity was found greater than 90% and the labeled compound was stable in human serum during incubation period up to 24 h. The improved kit was found to be sterile, pyrogen free and stable up to 6 months. According to gamma scintigraphy studies, 99mTc-CEF showed a higher uptake in bacterial infected and sterile inflamed muscle than healthy thigh muscle. © Copyright 2016 John Wiley & Sons, Ltd.
dc.identifier.DOI-ID10.1002/jlcr.3374
dc.identifier.issn03624803
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15927
dc.language.isoEnglish
dc.publisherJohn Wiley and Sons Ltd
dc.subjectAnimals
dc.subjectAnti-Bacterial Agents
dc.subjectBacterial Infections
dc.subjectCefotaxime
dc.subjectEscherichia coli
dc.subjectHumans
dc.subjectMuscle, Skeletal
dc.subjectPositron-Emission Tomography
dc.subjectRadiopharmaceuticals
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectSerum
dc.subjectTechnetium
dc.subjectTissue Distribution
dc.subjectcefotaxime sodium tc 99m
dc.subjectpyrogen
dc.subjecttracer
dc.subjectunclassified drug
dc.subjectantiinfective agent
dc.subjectcefotaxime
dc.subjectradiopharmaceutical agent
dc.subjecttechnetium
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectdrug distribution
dc.subjectEscherichia coli infection
dc.subjectfreeze drying
dc.subjectgamma scintigraphy
dc.subjecthigh performance liquid chromatography
dc.subjecthuman
dc.subjectin vivo study
dc.subjectinflammation
dc.subjectisotope labeling
dc.subjectnonhuman
dc.subjectradiation safety
dc.subjectradio high performance liquid chromatography
dc.subjectradio thin layer chromatography
dc.subjectradioactivity
dc.subjectradiochemistry
dc.subjectrat
dc.subjectthin layer chromatography
dc.subjectanimal
dc.subjectbacterial infection
dc.subjectchemistry
dc.subjectdiagnostic imaging
dc.subjectdrug effects
dc.subjectEscherichia coli
dc.subjectpositron emission tomography
dc.subjectserum
dc.subjectskeletal muscle
dc.subjectsynthesis
dc.subjecttissue distribution
dc.subjectWistar rat
dc.titleGamma scintigraphy and biodistribution of 99mTc-cefotaxime sodium in preclinical models of bacterial infection and sterile inflammation
dc.typeArticle

Files